Methylprednisolone is a drug from the group of glucocorticoids. Methylprednisolone is a derivative of the substance prednisolone. Methylprednisolone is administered orally and intramuscularly and is indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, respiratory, hematologic, neoplastic, edematous, gastrointestinal, nervous, and other conditions.
- neurodermatitis, contact eczema, hives, psoriasis
- acute and chronic lung diseases such as bronchial asthma and COPD
- rheumatic diseases such as lupus erythematosus, vasculitis, arthritis
- Crohn's disease and ulcerative colitis
The efficacy of methylprednisolone in coronavirus-related pneumonia is currently being evaluated in clinical trials.
Methylprednisolone was first synthesized and manufactured by the Upjohn Company (now Pfizer) and approved by the FDA in the United States in October 1957. Methylprednisolone is also on the World Health Organization's list of essential medicines.